Switching from Aromatase Inhibitors to Dual Targeting Flavonoid-Based Compounds for Breast Cancer Treatment
暂无分享,去创建一个
F. Belluti | A. Bisi | S. Gobbi | A. Rampa | N. Zaffaroni | A. Magistrato | Silvia Martini | A. Spinello | Jessica Caciolla | Riccardo Rozza
[1] A. Vinggaard,et al. An Exemestane Derivative, Oxymestane-D1, as a New Multi-Target Steroidal Aromatase Inhibitor for Estrogen Receptor-Positive (ER+) Breast Cancer: Effects on Sensitive and Resistant Cell Lines , 2023, Molecules.
[2] B. Ozpolat,et al. Molecular Mechanisms of Anti-Estrogen Therapy Resistance and Novel Targeted Therapies , 2022, Cancers.
[3] F. Belluti,et al. Single-digit nanomolar inhibitors lock the aromatase active site via a dualsteric targeting strategy. , 2022, European journal of medicinal chemistry.
[4] O. Sahin,et al. Endocrine resistance in breast cancer: from molecular mechanisms to therapeutic strategies , 2021, Journal of Molecular Medicine.
[5] Sébastien Fiorucci,et al. ProLIF: a library to encode molecular interactions as fingerprints , 2021, Journal of Cheminformatics.
[6] F. Belluti,et al. Balanced dual acting compounds targeting aromatase and estrogen receptor α as an emerging therapeutic opportunity to counteract estrogen responsive breast cancer. , 2021, European journal of medicinal chemistry.
[7] A. Magistrato,et al. Computing metal-binding proteins for therapeutic benefit. , 2021, ChemMedChem.
[8] P. Fernandes,et al. Discovery of a multi-target compound for estrogen receptor-positive (ER+) breast cancer: Involvement of aromatase and ERs. , 2020, Biochimie.
[9] Aakash Saha,et al. Frontiers of metal-coordinating drug design , 2020, Expert opinion on drug discovery.
[10] Alessandra Magistrato,et al. All-atom simulations to studying metallodrugs/target interactions. , 2020, Current opinion in chemical biology.
[11] Alessandra Magistrato,et al. Exploiting Cryo-EM Structural Information and All-Atom Simulations To Decrypt the Molecular Mechanism of Splicing Modulators , 2020, J. Chem. Inf. Model..
[12] P. Fernandes,et al. Estrogen receptor-positive (ER+) breast cancer treatment: are multi-target compounds the next promising approach? , 2020, Biochemical pharmacology.
[13] A. Bisi,et al. Targeting Orthosteric and Allosteric Pockets of Aromatase via Dual-Mode Novel Azole Inhibitors. , 2020, ACS medicinal chemistry letters.
[14] A. Frontera,et al. π‐Hole Interactions Involving Nitro Aromatic Ligands in Protein Structures , 2019, Chemistry.
[15] Alessandra Magistrato,et al. Post-Translational Regulation of CYP450s Metabolism As Revealed by All-Atoms Simulations of the Aromatase Enzyme , 2019, J. Chem. Inf. Model..
[16] A. Magistrato,et al. The Catalytic Mechanism of Steroidogenic Cytochromes P450 from All-Atom Simulations: Entwinement with Membrane Environment, Redox Partners, and Post-Transcriptional Regulation , 2019, Catalysts.
[17] L. Casalino,et al. A Dehydrogenase Dual Hydrogen Abstraction Mechanism Promotes Estrogen Biosynthesis: Can We Expand the Functional Annotation of the Aromatase Enzyme? , 2018, Chemistry.
[18] J. Schmit,et al. SLTCAP: A Simple Method for Calculating the Number of Ions Needed for MD Simulation. , 2018, Journal of chemical theory and computation.
[19] A. Bisi,et al. A Computational Assay of Estrogen Receptor α Antagonists Reveals the Key Common Structural Traits of Drugs Effectively Fighting Refractory Breast Cancers , 2018, Scientific Reports.
[20] E. Olson. Combination Therapies in Advanced, Hormone Receptor–Positive Breast Cancer , 2018, Journal of the advanced practitioner in oncology.
[21] T. Skaar,et al. Synthesis of Triphenylethylene Bisphenols as Aromatase Inhibitors That Also Modulate Estrogen Receptors. , 2016, Journal of medicinal chemistry.
[22] Alessandra Magistrato,et al. Role of Water in the Puzzling Mechanism of the Final Aromatization Step Promoted by the Human Aromatase Enzyme. Insights from QM/MM MD Simulations , 2015, J. Chem. Inf. Model..
[23] F. Lumachi,et al. Current medical treatment of estrogen receptor-positive breast cancer. , 2015, World journal of biological chemistry.
[24] C. Simmerling,et al. ff14SB: Improving the Accuracy of Protein Side Chain and Backbone Parameters from ff99SB. , 2015, Journal of chemical theory and computation.
[25] S. Genheden,et al. The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities , 2015, Expert opinion on drug discovery.
[26] T. Skaar,et al. Design and synthesis of norendoxifen analogues with dual aromatase inhibitory and estrogen receptor modulatory activities. , 2015, Journal of medicinal chemistry.
[27] D. Ghosh,et al. Evidence for an Elevated Aspartate pKa in the Active Site of Human Aromatase* , 2014, The Journal of Biological Chemistry.
[28] D. Ghosh,et al. Mechanism of inhibition of estrogen biosynthesis by azole fungicides. , 2014, Endocrinology.
[29] Holger Gohlke,et al. MMPBSA.py: An Efficient Program for End-State Free Energy Calculations. , 2012, Journal of chemical theory and computation.
[30] P. Perjési,et al. Structural studies of seven homoisoflavonoids, six thiohomoisoflavonoids, and four structurally related compounds , 2012, Structural Chemistry.
[31] Thomas E. Cheatham,et al. Quantum mechanically derived AMBER‐compatible heme parameters for various states of the cytochrome P450 catalytic cycle , 2012, J. Comput. Chem..
[32] Jan H. Jensen,et al. PROPKA3: Consistent Treatment of Internal and Surface Residues in Empirical pKa Predictions. , 2011, Journal of chemical theory and computation.
[33] A. Bisi,et al. Novel aldosterone synthase inhibitors with extended carbocyclic skeleton by a combined ligand-based and structure-based drug design approach. , 2008, Journal of medicinal chemistry.
[34] T. Cheatham,et al. Determination of Alkali and Halide Monovalent Ion Parameters for Use in Explicitly Solvated Biomolecular Simulations , 2008, The journal of physical chemistry. B.
[35] V. V. Zhurov,et al. Binding of genistein to the estrogen receptor based on an experimental electron density study. , 2007, Journal of the American Chemical Society.
[36] Joost VandeVondele,et al. Gaussian basis sets for accurate calculations on molecular systems in gas and condensed phases. , 2007, The Journal of chemical physics.
[37] M. Parrinello,et al. Canonical sampling through velocity rescaling. , 2007, The Journal of chemical physics.
[38] P. Kollman,et al. Automatic atom type and bond type perception in molecular mechanical calculations. , 2006, Journal of molecular graphics & modelling.
[39] A. Cavalli,et al. Lead optimization providing a series of flavone derivatives as potent nonsteroidal inhibitors of the cytochrome P450 aromatase enzyme. , 2006, Journal of medicinal chemistry.
[40] Gerrit Groenhof,et al. GROMACS: Fast, flexible, and free , 2005, J. Comput. Chem..
[41] Silvia Gobbi,et al. Enantioselective nonsteroidal aromatase inhibitors identified through a multidisciplinary medicinal chemistry approach. , 2005, Journal of medicinal chemistry.
[42] B. Bonanni,et al. SERMs in chemoprevention of breast cancer. , 2005, European journal of cancer.
[43] A. Brodie,et al. Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model. , 2005, Cancer research.
[44] Michele Parrinello,et al. Quickstep: Fast and accurate density functional calculations using a mixed Gaussian and plane waves approach , 2005, Comput. Phys. Commun..
[45] M Baum,et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer , 2005, The Lancet.
[46] Junmei Wang,et al. Development and testing of a general amber force field , 2004, J. Comput. Chem..
[47] Matthew P. Repasky,et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. , 2004, Journal of medicinal chemistry.
[48] Hege S. Beard,et al. Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. , 2004, Journal of medicinal chemistry.
[49] J. Cuzick,et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early‐stage breast cancer , 2003, Cancer.
[50] M. Dowsett. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer. Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses , 2003 .
[51] P. Kollman,et al. Combined molecular mechanical and continuum solvent approach (MM-PBSA/GBSA) to predict ligand binding , 2000 .
[52] X. Daura,et al. Folding–unfolding thermodynamics of a β‐heptapeptide from equilibrium simulations , 1999, Proteins.
[53] Zbigniew Dauter,et al. Molecular basis of agonism and antagonism in the oestrogen receptor , 1997, Nature.
[54] Berk Hess,et al. LINCS: A linear constraint solver for molecular simulations , 1997, J. Comput. Chem..
[55] K Schulten,et al. VMD: visual molecular dynamics. , 1996, Journal of molecular graphics.
[56] M. Teter,et al. Separable dual-space Gaussian pseudopotentials. , 1995, Physical review. B, Condensed matter.
[57] T. Darden,et al. Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems , 1993 .
[58] S. Nosé. A unified formulation of the constant temperature molecular dynamics methods , 1984 .
[59] W. L. Jorgensen,et al. Comparison of simple potential functions for simulating liquid water , 1983 .
[60] M. Parrinello,et al. Polymorphic transitions in single crystals: A new molecular dynamics method , 1981 .
[61] Jian Yin,et al. Lessons learned from comparing molecular dynamics engines on the SAMPL5 dataset , 2016, bioRxiv.
[62] M. Castiglione‐Gertsch,et al. Estrogen Receptor Modulators and Down Regulators , 2012, Drugs.
[63] David A. Flockhart,et al. Tamoxifen metabolites as active inhibitors of aromatase in the treatment of breast cancer , 2011, Breast Cancer Research and Treatment.